Among additional repurposing drug candidates that could improve anti-tumor immune response, it was reported that, in analogy to PCSK9 deletion, PCSK9-neutralizing antibodies, clinically approved for hypercholesterolemia treatment, synergize with anti-PD1 therapy in different mouse cancer models. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.